MILPITAS, Calif., March 02, 2017 -- Lumentum Holdings Inc. (“Lumentum”) (NASDAQ:LITE) today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate principal amount of convertible senior notes due in 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Act”). Lumentum also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $52.5 million aggregate principal amount of the notes, solely to cover over-allotments, if any.
The notes will be unsecured, senior obligations of Lumentum, and interest will be payable semi-annually in arrears. The notes will be convertible at the option of holders, subject to certain conditions and during certain periods, into cash, shares of Lumentum’s common stock or a combination of cash and shares of Lumentum’s common stock, with the form of consideration at Lumentum’s election. However, the notes will not be convertible into Lumentum’s common stock, and Lumentum will satisfy its conversion obligation solely in cash, until such time as Lumentum satisfies certain restrictions contained in the indenture for the notes. The interest rate, conversion rate and certain other terms of the notes are to be determined upon pricing of the offering.
Lumentum intends to use the net proceeds of the offering for general corporate purposes, which may include capital expenditures, including manufacturing capacity expansion, and working capital.
The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Act. Neither the notes nor the shares of common stock issuable upon conversion of the notes, if any, have been, nor will be, registered under the Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding Lumentum’s ability to complete the offering, the expected closing date of the offering and Lumentum’s intended use of the net proceeds of the offering. Forward looking statements may also be identified by the use of the words “may,” “might,” “will,” “should,” “estimate,” “project,” “plan,” “anticipate,” “expect,” “intend,” “outlook,” “believe” and other similar expressions. These forward looking statements are based on estimates and assumptions by Lumentum’s management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. Actual results may differ materially from those anticipated or predicted by Lumentum’s forward-looking statements as a result of various important factors, including, but not limited to, the terms of the notes and the offering, the risks and uncertainties related to whether or not Lumentum will consummate the offering, and the impact of general economic, industry, market or political conditions. In addition, all forward-looking statements are subject to other risks detailed in our Quarterly Report on Form 10-Q for the quarter ended December 31, 2016 and the risks discussed in our other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof, except as required by applicable law.
Press: Greg Kaufman (408) 546-4235 [email protected] Investors: Chris Coldren (408) 404-0606 [email protected]


Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 



